Leon Clark, MD
Dermatology · Rancho Mirage, CANPI 1487004370
Payments from drug & device makers
Across 30 payments — averaging $507.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$12K
- E.r. Squibb & Sons, L.L.C.$2K
- AbbVie$359
- LEO Pharma Inc.$62
- UCB, Inc.$46
- Janssen Scientific Affairs, LLC$23
- plus $22 from 1 others
What the payments were for
- Consulting fees$2,20514%
- Speaking & faculty fees$12,30081%
- Food & beverage$7115%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 8 | $12,499 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,215 |
| AbbVie | 13 | $359 |
| LEO Pharma Inc. | 3 | $62 |
| UCB, Inc. | 2 | $46 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEMLUVIO$12,450
How this compares
$15,227 in reported general payments places this provider in the 80th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 18 | $327,657 |
| Dupixent PenDupilumab | 63 | $225,200 |
| Humira(Cf) PenAdalimumab | 12 | $154,729 |
| Taltz AutoinjectorIxekizumab | 19 | $116,209 |
| Calcipotriene | 24 | $8,864 |
| Fluocinonide | 44 | $2,025 |
| Clobetasol Propionate | 31 | $1,837 |
| Betamethasone Dipropionate | 42 | $1,810 |
| Triamcinolone Acetonide | 47 | $1,205 |
| Halobetasol Propionate | 11 | $947 |
| Clindamycin Phosphate | 13 | $944 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $652 |
| Ketoconazole | 14 | $276 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 19 | $174 |
| Hydrocortisone | 28 | $86 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Rancho Mirage
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
- Paul YamauchiSanta Monica$7.8M
- Navid EzraThousand Oaks$7.8M
- Paul WallaceBeverly Hills$7.1M
- April ArmstrongLos Angeles$6.2M
- David RayhanHuntington Beach$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.